Trial Profile
A Phase 1, Open Label, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Medarex
- 28 Jan 2023 Results assessing safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates published in the Journal of Clinical Oncology
- 22 May 2019 Results of Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients using data from 2 predominantly Chinese and 5 global studies, published in the Journal of Clinical Pharmacology
- 15 May 2019 Results of PPK analysis using data from multiple clinical studies in patients with AdjMEL, MEL, NSCLC, and other tumor types (CA209-001, CA209-003, CA209-005, CA209-017, CA209-057, CA209-037, CA209-066, CA209-238, CA209-063 and CA209-051) published in the Clinical Pharmacology and Therapeutics